Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant alkaline phosphatase - AM-Pharma Holding

Drug Profile

Recombinant alkaline phosphatase - AM-Pharma Holding

Alternative Names: Human recombinant alkaline phosphatase; recAP; Recombinant optimised human alkaline phosphatase

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AM-Pharma Holding
  • Developer AM-Pharma
  • Class Recombinant proteins
  • Mechanism of Action Endotoxin inhibitors; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypophosphatasia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase II Acute kidney injury
  • No development reported Hypophosphatasia; Ulcerative colitis
  • Discontinued Septic shock

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for preclinical development in Hypophosphatasia in Netherlands (SC, Injection)
  • 09 Mar 2018 Interim efficacy and adverse events data from the phase II STOP-AKI trial in Acute kidney injury released by AM-Pharma Holding
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ulcerative-colitis in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top